(S042) Phase I–III Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience Over 30 Years
We present demographics and factors associated with slow trial accrual at MDACC. We believe that this analysis serves as a baseline and highlights areas of weakness to aid in the development of evidence-based trial guidelines.
Chad Tang, MD, Steven I. Sherman, MD, Mellanie Price, Jun Weng, Suzanne Davis, MBA, MMS, David Hong, MD, Aman Buzdar, MD, J. J. Lee, PhD, MS, DDS; UT MD Anderson Cancer Center
PURPOSE: Increasingly limited resources mandate the careful allocation of assets for cancer research. Slow-accruing clinical trials delay the translation of biomedical research, contribute to increasing healthcare costs, and often languish unfinished. We analyzed The University of Texas MD Anderson Cancer Center (MDACC) experience for factors that predict slow participant accrual to phase I–III trials.
MATERIALS AND METHODS: Clinical Oncology Research system (CORe) is a prospectively maintained institutional database that tracks all clinical studies at MDACC. We evaluated studies that met the following inclusion criteria: activated phase I–III trials, maximum projected accrual ≥ 10 participants, and activation prior to March 2011. The primary outcome was slow accrual, defined as an accrual rate of < 2 participants per year. Correlations of trial characteristics and development variables with slow accrual were assessed with univariate and multivariate logistic regression. Additional slow accrual cutpoints and a Bonferroni-adjusted significance threshold of P < .003 were utilized to ensure robust associations.
RESULTS: A total of 4,269 clinical trials met the inclusion criteria. Trials were activated between 1981 and 2011, with 145,214 participants enrolled. Median total enrollment was 17 (interquartile range [IQR]: 6–38), with an average rate of 8.7 participants/year (IQR: 3.3–17.7). There were 755 (18%) trials classified as slow-accruing.
On multivariate analysis, slow accrual exhibited robust associations with national cooperative group trials (odds ratio [OR], 4.16; P < .0001 vs industry-sponsored) and time from trial activation to first enrollment (OR, 1.13 per month; P < .0001). Factors that were not robustly associated with slow accrual included the number of concurrent trials activated within the same department, year of trial activation, and trial phase. Slow-accruing trials led to a lower rate of peer-reviewed publication (14%) than non–slow-accruing trials (69%).
CONCLUSIONS: We present demographics and factors associated with slow trial accrual at MDACC. We believe that this analysis serves as a baseline and highlights areas of weakness to aid in the development of evidence-based trial guidelines.
Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
